Awards 2023. 04. 28
On the evening of April 26, China Healthcare Consulting and CITIC Securities officially released the "2022 China Healthcare Industry Investment and Financing Honor List". As an authoritative list showing the investment and financing trend of China's healthcare industry, this year's Honor List selected a total of 14 awards in four categories: investment institutions, enterprises, investors, and law firms. With its outstanding performance in 2022, Innorna was listed in the "2022 Top 50 Enterprises with the Most Investment Value in Healthcare".
"China Healthcare Industry Investment and Financing Honor List" was jointly launched by CHC and CITIC Securities. Through data statistics, horizontal comparison, and full-dimensional dialysis, investment institutions, investors, innovative companies and other industry participants were selected for their outstanding contributions and the industry benchmarks they set up.
Value comes from innovation and scarcity. Since its establishment, Innorna has always had science and innovation as its driving forces, devoted itself to building a technology platform with independent intellectual property rights, and built more than 5,000 kinds of LNP libraries suitable for different application scenarios. This is how Innorna has become one of the few companies in the world that truly possesses the underlying technology of mRNA delivery. At present, Innorna has reached cooperation with many well-known domestic and foreign companies to jointly explore the development potential of mRNA and LNP platform technology in vaccines, gene editing, tumor immunity and other therapeutic fields, and gradually convert the value of the technology platform into clinical application value.
Thanks to colleagues in the industry for their recognition of Innorna, and look forward to continuing to walk together in the future.